DiaSorin S.p.A. (OTCMKTS:DSRLF) Receives Average Recommendation of “Strong Sell” from Analysts

Shares of DiaSorin S.p.A. (OTCMKTS:DSRLF) have been given a consensus recommendation of “Strong Sell” by the five brokerages that are presently covering the company, MarketBeat reports. Four equities research analysts have rated the stock with a sell rating and one has issued a hold rating on the company.

Several research analysts recently issued reports on the stock. Zacks Research cut shares of DiaSorin from a “hold” rating to a “strong sell” rating in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating on shares of DiaSorin in a report on Tuesday, August 4th. UBS Group downgraded DiaSorin from a “hold” rating to a “sell” rating in a research report on Wednesday, August 12th. Piper Sandler assumed coverage on DiaSorin in a research note on Thursday, June 11th. They set a “neutral” rating for the company. Finally, BNP Paribas Exane cut DiaSorin from a “neutral” rating to an “underperform” rating in a report on Tuesday, July 7th.

DiaSorin Stock Performance

Shares of OTCMKTS DSRLF opened at $86.00 on Friday. The company has a 50 day simple moving average of $81.00 and a two-hundred day simple moving average of $76.82. DiaSorin has a 12 month low of $66.50 and a 12 month high of $100.00.

DiaSorin Company Profile

DiaSorin S.p.A. is an Italy‐based global biotechnology company specializing in the development, manufacture and marketing of in vitro diagnostic products. Headquartered in Saluggia, DiaSorin serves clinical laboratories, hospitals and physician offices with a broad portfolio of immunodiagnostic assays and molecular diagnostic tests. The company’s shares trade on the Milan Stock Exchange and are available in the United States as over‐the‐counter (OTC) securities under the symbol DSRLF.

At the core of DiaSorin’s business are immunodiagnostic systems that measure antibodies, antigens and hormones in human samples.